A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure

Rationale, design, and baseline patient characteristics

William T. Abraham, Daniel Burkhoff, Koonlawee Nademanee, Peter Carson, Robert Bourge, Kenneth A. Ellenbogen, Michael K. Parides, Alan Kadish

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the cardiac absolute refractory period that enhance the strength of cardiac muscular contraction. Prior research in experimental and human heart failure has shown that CCM signals normalize phosphorylation of key proteins and expression of genes coding for proteins involved in regulation of calcium cycling and contraction. The results of prior clinical studies of CCM have supported its safety and efficacy. A large-scale clinical study, the FIX-HF-5 study, is currently underway to test the safety and efficacy of this treatment. In this article, we provide an overview of the system used to deliver CCM signals, the implant procedure, and the details and rationale of the FIX-HF-5 study design. Baseline characteristics for patients randomized in this trial are also presented.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume156
Issue number4
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Systolic Heart Failure
Randomized Controlled Trials
Safety
Muscle Contraction
Proteins
Heart Failure
Phosphorylation
Calcium
Research
Clinical Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure : Rationale, design, and baseline patient characteristics. / Abraham, William T.; Burkhoff, Daniel; Nademanee, Koonlawee; Carson, Peter; Bourge, Robert; Ellenbogen, Kenneth A.; Parides, Michael K.; Kadish, Alan.

In: American Heart Journal, Vol. 156, No. 4, 01.10.2008.

Research output: Contribution to journalArticle

Abraham, William T. ; Burkhoff, Daniel ; Nademanee, Koonlawee ; Carson, Peter ; Bourge, Robert ; Ellenbogen, Kenneth A. ; Parides, Michael K. ; Kadish, Alan. / A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure : Rationale, design, and baseline patient characteristics. In: American Heart Journal. 2008 ; Vol. 156, No. 4.
@article{4ca29e0aacb84608a7b550beae271d73,
title = "A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics",
abstract = "Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the cardiac absolute refractory period that enhance the strength of cardiac muscular contraction. Prior research in experimental and human heart failure has shown that CCM signals normalize phosphorylation of key proteins and expression of genes coding for proteins involved in regulation of calcium cycling and contraction. The results of prior clinical studies of CCM have supported its safety and efficacy. A large-scale clinical study, the FIX-HF-5 study, is currently underway to test the safety and efficacy of this treatment. In this article, we provide an overview of the system used to deliver CCM signals, the implant procedure, and the details and rationale of the FIX-HF-5 study design. Baseline characteristics for patients randomized in this trial are also presented.",
author = "Abraham, {William T.} and Daniel Burkhoff and Koonlawee Nademanee and Peter Carson and Robert Bourge and Ellenbogen, {Kenneth A.} and Parides, {Michael K.} and Alan Kadish",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.ahj.2008.05.019",
language = "English (US)",
volume = "156",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure

T2 - Rationale, design, and baseline patient characteristics

AU - Abraham, William T.

AU - Burkhoff, Daniel

AU - Nademanee, Koonlawee

AU - Carson, Peter

AU - Bourge, Robert

AU - Ellenbogen, Kenneth A.

AU - Parides, Michael K.

AU - Kadish, Alan

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the cardiac absolute refractory period that enhance the strength of cardiac muscular contraction. Prior research in experimental and human heart failure has shown that CCM signals normalize phosphorylation of key proteins and expression of genes coding for proteins involved in regulation of calcium cycling and contraction. The results of prior clinical studies of CCM have supported its safety and efficacy. A large-scale clinical study, the FIX-HF-5 study, is currently underway to test the safety and efficacy of this treatment. In this article, we provide an overview of the system used to deliver CCM signals, the implant procedure, and the details and rationale of the FIX-HF-5 study design. Baseline characteristics for patients randomized in this trial are also presented.

AB - Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the cardiac absolute refractory period that enhance the strength of cardiac muscular contraction. Prior research in experimental and human heart failure has shown that CCM signals normalize phosphorylation of key proteins and expression of genes coding for proteins involved in regulation of calcium cycling and contraction. The results of prior clinical studies of CCM have supported its safety and efficacy. A large-scale clinical study, the FIX-HF-5 study, is currently underway to test the safety and efficacy of this treatment. In this article, we provide an overview of the system used to deliver CCM signals, the implant procedure, and the details and rationale of the FIX-HF-5 study design. Baseline characteristics for patients randomized in this trial are also presented.

UR - http://www.scopus.com/inward/record.url?scp=52949139748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949139748&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2008.05.019

DO - 10.1016/j.ahj.2008.05.019

M3 - Article

VL - 156

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -